Dalfampridine
- Generic Name
- Dalfampridine
- Brand Names
- Ampyra, Fampyra, Fampridine Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C5H6N2
- CAS Number
- 504-24-5
- Unique Ingredient Identifier
- BH3B64OKL9
- Background
Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
- Indication
Dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis (MS).
- Associated Conditions
- Multiple Sclerosis
- Associated Therapies
- -
Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis
- Conditions
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Genesis Pharma CNS & Specialty
- Target Recruit Count
- 111
- Registration Number
- NCT03164018
- Locations
- 🇬🇷
Αiginitio hospital, Athens, Attika, Greece
Use of Dalfampridine in Primary Lateral Sclerosis
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Hospital for Special Surgery, New York
- Target Recruit Count
- 35
- Registration Number
- NCT02868567
- Locations
- 🇺🇸
University of Florida Gainsville, Gainesville, Florida, United States
🇺🇸Mass General Hospital, Boston, Massachusetts, United States
🇺🇸Shara Holzberg, New York, New York, United States
Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 89
- Registration Number
- NCT02849782
- Locations
- 🇫🇷
CHU Jean Minjoz, Besancon, France
Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy Adults
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 13
- Registration Number
- NCT02656160
- Locations
- 🇺🇸
Sleep Disorders Research Program Brigham and Women's Hospital, Boston, Massachusetts, United States
Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 23
- Registration Number
- NCT02391961
- Locations
- 🇺🇸
Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States
Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Coordinación de Investigación en Salud, Mexico
- Target Recruit Count
- 24
- Registration Number
- NCT02280096
- Locations
- 🇲🇽
Hospital de Especialidades, CMN Siglo XXI, Mexico City, Distrito Federal, Mexico
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- Biogen
- Target Recruit Count
- 646
- Registration Number
- NCT02219932
- Locations
- 🇷🇺
Research Site, Nizhny Novgorod, Russian Federation
🇬🇧Research site, Nottingham, United Kingdom
A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS
- Conditions
- Interventions
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- University College Dublin
- Target Recruit Count
- 64
- Registration Number
- NCT02208050
- Locations
- 🇮🇪
St Vincent's University Hospital, Dublin, Dublin 4, Ireland
🇮🇪St. Vincents University Hospital, Dublin, Ireland
Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)
- Conditions
- Interventions
- First Posted Date
- 2014-06-18
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 24
- Registration Number
- NCT02166346
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Effects of Dalfampridine on Cognition in Multiple Sclerosis
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 61
- Registration Number
- NCT02006160
- Locations
- 🇺🇸
Buffalo General Hospital, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.